Affymax (OTCMKTS:AFFY – Get Free Report) and TG Therapeutics (NASDAQ:TGTX – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership and dividends.
Volatility and Risk
Affymax has a beta of 6.39, suggesting that its stock price is 539% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.25, suggesting that its stock price is 125% more volatile than the S&P 500.
Earnings and Valuation
This table compares Affymax and TG Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Affymax | N/A | N/A | N/A | N/A | N/A |
| TG Therapeutics | $264.79 million | 18.93 | $12.67 million | ($0.10) | -322.00 |
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Affymax and TG Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Affymax | 0 | 0 | 0 | 0 | 0.00 |
| TG Therapeutics | 0 | 1 | 5 | 0 | 2.83 |
TG Therapeutics has a consensus price target of $40.67, suggesting a potential upside of 26.29%. Given TG Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe TG Therapeutics is more favorable than Affymax.
Institutional & Insider Ownership
58.6% of TG Therapeutics shares are owned by institutional investors. 1.6% of Affymax shares are owned by company insiders. Comparatively, 10.5% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares Affymax and TG Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Affymax | N/A | N/A | N/A |
| TG Therapeutics | -5.42% | -8.32% | -3.40% |
Summary
TG Therapeutics beats Affymax on 6 of the 10 factors compared between the two stocks.
About Affymax
Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.
About TG Therapeutics
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
Receive News & Ratings for Affymax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affymax and related companies with MarketBeat.com's FREE daily email newsletter.
